Opioid Addiction Treatment Behind Bars: Legal Duties and Evolving Practice
How a landmark First Circuit ruling is reshaping the obligation of jails and prisons to provide evidence-based addiction treatment.
Across the United States, jails and prisons hold a disproportionate number of people with serious substance use disorders, especially opioid addiction. At the same time, correctional systems have historically offered limited or no access to evidence-based care, including medication-assisted treatment (MAT) for opioid use disorder. Recent federal court decisions, including a notable ruling from the U.S. Court of Appeals for the First Circuit, are beginning to change that landscape by framing addiction treatment as both a legal obligation and a matter of disability rights.
This article explains why addiction treatment behind bars has become a critical legal and public health issue, what the First Circuit decision means, how medication-assisted treatment works, and how correctional systems can adapt their practices. It also addresses common concerns and provides answers to frequently asked questions.
The Scale of Addiction in Jails and Prisons
Research consistently shows that individuals in the criminal justice system experience substance use disorders at far higher rates than the general population. Many enter jail or prison with long histories of opioid use, dependence, and prior overdose, making incarceration a pivotal moment either for harm or for effective intervention.
- High prevalence: Studies find that a large share of people in custody meet criteria for a substance use disorder, with opioid use disorder (OUD) particularly common among those cycling through local jails.
- Missed opportunities: Given jails’ high admission volume and rapid turnover, they represent a significant but often underused point for screening, brief intervention, and referral to treatment.
- Overdose risk after release: Leaving custody is a period of extreme vulnerability. One major study cited in rights advocacy materials found that providing MAT in custody can reduce overdose deaths after release by about 85% and all-cause mortality by roughly 75% in the first weeks, highlighting the life-saving potential of treatment access.
Despite this, many jails and prisons historically relied on abrupt withdrawal or short-term detox without continuing care. That approach has increasingly been challenged as inconsistent with modern medical standards and, in some circumstances, unlawful.
Medication-Assisted Treatment: What It Is and Why It Matters
Medication-assisted treatment (sometimes referred to as medication for opioid use disorder, or MOUD) integrates FDA-approved medications with counseling and behavioral therapies to address opioid addiction. It is regarded as the standard of care by major health authorities.
Core Components of MAT
- Methadone: A long-acting opioid agonist dispensed under strict regulation, usually through licensed opioid treatment programs.
- Buprenorphine: A partial agonist that reduces cravings and withdrawal symptoms, often combined with naloxone in formulations used to treat OUD.
- Naltrexone: An opioid antagonist that blocks the effects of opioids; an extended-release injectable form is sometimes used in correctional or reentry programs.
When combined with counseling, peer support, and reentry planning, MAT has been shown to reduce illicit opioid use, improve treatment retention, and lower the risk of overdose. This evidence has informed recent litigation arguing that denying such treatment to incarcerated people with OUD can amount to discrimination or deliberate indifference.
A Landmark First Circuit Decision: The Right to Treatment in Jail
In a widely reported case, the U.S. Court of Appeals for the First Circuit in Boston considered whether a rural jail in Maine could refuse to provide a woman with her prescribed buprenorphine during her incarceration. She had long-standing opioid use disorder and was receiving medication in the community prior to entering custody.
The First Circuit upheld an order requiring the jail to continue her medication, finding that the jail’s blanket denial of MAT likely violated the Americans with Disabilities Act (ADA) and related federal protections.
Key Legal Points from the First Circuit Ruling
| Issue | Court’s View | Implication for Jails |
|---|---|---|
| Opioid use disorder as a disability | The court treated OUD as a qualifying disability under the ADA when it substantially limits major life activities. | Jails must recognize OUD as a protected condition, not simply a criminal or moral issue. |
| Blanket bans on MAT | A general policy refusing MAT, regardless of medical need, was characterized as unreasonable and discriminatory. | Facilities cannot rely on blanket security or philosophical objections to justify denying indicated medications. |
| Reasonable modification | Continuing a preexisting prescription was viewed as a reasonable modification of jail procedures under the ADA. | Jails must adjust routines where practicable to accommodate people with OUD and maintain necessary medications. |
Although the case focused on one plaintiff and one jail, it is the first federal appellate decision to directly address the right to opioid addiction medication in jail settings. Legal advocates expect courts around the country to consider its reasoning when evaluating similar policies, giving it influence well beyond the First Circuit states.
Legal Framework: Disability Rights and Constitutional Duties
The obligation to provide addiction treatment in correctional settings arises from overlapping legal regimes. Two are particularly important: disability discrimination law and constitutional protections for incarcerated people.
Americans with Disabilities Act (ADA)
- Coverage: Title II of the ADA prohibits public entities, including state and local correctional facilities, from discriminating against qualified individuals with disabilities in services, programs, or activities.
- Reasonable modifications: Facilities must make reasonable changes to policies and practices to avoid discrimination, unless doing so would fundamentally alter the nature of the service or create undue burdens.
- Application to OUD: Courts and policy bodies have increasingly recognized opioid use disorder as a disability when it substantially limits major life activities, particularly where individuals are in recovery or actively engaged in treatment.
Under this framework, a jail that refuses to continue clinically indicated MAT – while providing other types of medical care – may be discriminating based on disability. The First Circuit’s decision explicitly linked denial of buprenorphine to ADA violations, setting a significant precedent.
Eighth Amendment and Due Process Considerations
In addition to the ADA, incarcerated individuals retain certain constitutional rights. The Eighth Amendment (for convicted prisoners) and the Due Process Clause (for pretrial detainees) have been interpreted to require adequate medical care and to forbid deliberate indifference to serious medical needs.
- Serious medical need: Courts typically treat conditions like opioid use disorder and severe withdrawal risk as serious medical needs that warrant treatment.
- Deliberate indifference: Persistently ignoring known medical risks, or adopting rigid policies that foreseeably cause harm, can lead to liability for correctional officials.
When jails or prisons deny MAT despite clear medical indications and known overdose risks after release, they may run afoul of these constitutional requirements as well, strengthening the argument that treatment is not merely optional but legally necessary.
Operational Challenges and Practical Solutions in Jail Settings
Providing addiction treatment in jails is challenging. Local facilities often have short average stays, frequent turnover, limited clinical staff, and security concerns about medication diversion. Yet research and practice show that these obstacles can be addressed through careful design.
Unique Constraints in Jails
- Short length of stay: Many detainees are held only for days or weeks, making it difficult to implement long-term treatment programs.
- Resource limitations: Smaller or rural jails may lack on-site addiction specialists and rely on external providers.
- Security concerns: Staff may worry that controlled medications like buprenorphine or methadone could be misused or traded.
Evidence-Based Strategies
Despite these constraints, several strategies have been identified as compatible with jail environments.
- Screening and brief intervention: Systematic intake screening for substance use, followed by brief counseling and motivational interviewing, can identify individuals who need treatment and increase willingness to engage in care.
- Initiating or continuing MAT: For people already on MAT, continuing prescribed medications during incarceration avoids destabilization and reduces post-release overdose risk. For others, carefully managed initiation may be appropriate, especially for those with more stable or longer jail stays.
- Coordination with community providers: Linking detainees to community-based MAT programs and drug courts upon release improves continuity of care and significantly reduces recidivism and drug use.
- Staff training and protocols: Training correctional staff on addiction science and MAT, along with clear diversion-prevention protocols, addresses security concerns while supporting recovery-focused practice.
Randomized trials and meta-analyses of treatment programs connected to the criminal justice system—including therapeutic communities and specialized drug courts—demonstrate reductions in drug use and reoffending when evidence-based interventions are offered. Jails that incorporate MAT into broader rehabilitative strategies can therefore meet legal duties and advance public safety.
Policy Momentum: Litigation and Legislative Change
The First Circuit decision did not occur in isolation. Across several states, lawsuits and settlement agreements have prompted corrections agencies to reform policies regarding MAT access.
Litigation-Driven Reform
- ADA-based lawsuits: Individuals with OUD have challenged jail and prison policies that categorically refuse MAT or terminate treatment upon entry, arguing these policies are discriminatory.
- Federal court outcomes: In multiple cases, federal courts have ordered facilities to provide or maintain MAT and have affirmed that failing to do so can violate federal law.
Policy analysts tracking these cases note that decisions mandating access to MAT are prompting state departments of corrections and local jails to reconsider their practices in order to comply with the ADA and avoid liability.
Legislative and Administrative Responses
In parallel with litigation, some states have enacted laws or adopted administrative rules recognizing MAT as medically necessary for incarcerated people with opioid use disorder and directing facilities to provide or facilitate access where clinically indicated.
- Statutory recognition of MAT: One state law, for example, expressly declares that MAT in correctional facilities is a medically necessary component of treatment for inmates with opioid use disorder and defines the term accordingly.
- Program expansion: State maps compiled by health policy organizations show a growing number of prison systems now offering MOUD services, with many local jails beginning to follow suit.
Although implementation remains uneven, these changes suggest a trend toward treating addiction behind bars as a health issue subject to modern standards of care rather than as a matter solely of discipline or punishment.
Integrating Treatment with Reentry and Recidivism Reduction
Effective addiction treatment in custody is closely linked to outcomes after release. When corrections agencies integrate MAT with reentry planning, they can reduce both overdose risk and future criminal behavior.
Key Elements of Successful Reentry-Oriented Treatment
- Continuity of care: Ensuring that individuals transition directly from in-jail or in-prison MAT to community-based providers, without gaps in medication, is crucial to avoid relapse and overdose.
- Drug courts and diversion: Specialized courts and diversion programs that connect defendants to treatment rather than incarceration have been shown to reduce recidivism significantly; one meta-analysis found participation lowered recidivism rates from approximately 50% to 38% on average.
- Supportive services: Housing, employment assistance, and peer recovery supports complement medication and counseling, helping to stabilize life circumstances and reduce pressure to return to substance use.
Federal reforms such as the First Step Act have also emphasized risk and needs assessments, encouraging correctional systems to identify criminogenic needs—including substance use disorders—and to place people in programming that reduces those risks. While such legislation does not itself mandate MAT, it aligns with the broader shift toward evidence-based rehabilitation.
Addressing Common Questions and Concerns
FAQs on Addiction Treatment in Jails and Prisons
1. Is a jail or prison legally required to provide MAT to every person with opioid use disorder?
No facility is required to provide a specific medication in every case, but courts and policymakers increasingly expect jails and prisons to offer clinically appropriate treatment options and to avoid categorical bans. Under the ADA, denying MAT solely because of a general policy, rather than an individualized medical assessment, can be discriminatory.
2. Does providing MAT in jail increase security risks?
Security risks, such as diversion, must be taken seriously, but they can be managed through careful protocols, supervised dosing, and staff training. Health and policy sources emphasize that the benefits—including reduced overdose deaths and improved engagement in treatment—outweigh the manageable risks when programs are properly designed.
3. Isn’t forced withdrawal sufficient to address addiction during incarceration?
Abrupt withdrawal addresses neither the chronic nature of opioid use disorder nor the long-term risk of relapse and overdose. Modern standards of care treat OUD as a chronic condition requiring ongoing management. Studies linking MAT during incarceration to dramatic reductions in post-release mortality underscore that withdrawal alone is inadequate and potentially dangerous.
4. How does the First Circuit ruling affect other states?
The decision directly binds jails and prisons within the First Circuit (Maine, Massachusetts, New Hampshire, Puerto Rico, and Rhode Island) but is persuasive authority elsewhere. Courts in other circuits may look to its reasoning when considering similar cases, and corrections systems nationwide are watching it as they revise policies to comply with federal law.
5. What role do drug courts play in this landscape?
Drug courts operate as part of the criminal justice system’s broader response to substance use. They often mandate treatment and close supervision rather than traditional incarceration. Over the last 15 years, randomized trials and meta-analyses have found that adult drug courts reduce both drug use and criminal behavior during participation and lower recidivism after completion. When linked to MAT, they can be a powerful tool for long-term recovery.
Looking Ahead: From Exception to Standard Practice
The First Circuit’s recognition of a right to continue prescribed buprenorphine in jail is a significant milestone in the ongoing evolution of correctional health care. Combined with growing policy momentum, empirical evidence, and advocacy, it points toward a future in which evidence-based addiction treatment is a standard part of incarceration rather than an exception.
- For correctional leaders: Investing in MAT programs, staff education, and partnerships with community providers can reduce legal risk, save lives, and promote safer communities.
- For policymakers: Clarifying obligations through legislation and funding can help ensure that all incarcerated people with opioid use disorder have access to medically necessary treatment.
- For advocates and families: Understanding the legal framework and emerging precedents can support efforts to secure appropriate care for loved ones behind bars.
As research continues to demonstrate the benefits of treatment and courts increasingly view denial of care as incompatible with disability and constitutional protections, the expectation that jails and prisons must provide meaningful addiction treatment — including MAT — is likely to strengthen. The challenge ahead lies in translating legal rights and policy commitments into consistent, high-quality practice across thousands of diverse facilities.
References
- Setting Precedent, A Federal Court Rules Jail Must Give Inmate Addiction Treatment — NPR. 2019-05-04. https://www.npr.org/sections/health-shots/2019/05/04/719805278/setting-precedent-a-federal-court-rules-jail-must-give-inmate-addiction-treatmen
- Treating Substance Use Disorders in the Criminal Justice System — Chandler RK et al., Curr Psychiatry Rep (PMC). 2013-12-01. https://pmc.ncbi.nlm.nih.gov/articles/PMC3859122/
- Court paves the way for addiction treatment in prisons and jails — STAT. 2019-06-10. https://www.statnews.com/2019/06/10/opioid-addiction-treatment-correctional-facilities/
- How the Failure to Provide Treatment for Substance Use in Prisons and Jails Constitutes Discrimination — American Civil Liberties Union (ACLU). 2021-06-25. https://www.aclu.org/wp-content/uploads/publications/20210625-mat-prison_1.pdf
- Litigation Prompting State and Local Correctional Systems to Change Opioid Use Disorder Treatment Policies — National Academy for State Health Policy (NASHP). 2019-10-01. https://nashp.org/litigation-prompting-state-and-local-correctional-systems-to-change-opioid-use-disorder-treatment-policies/
- Addiction Treatment in Correctional Settings — Palo Alto University Business of Practice Blog. 2023-03-15. https://paloaltou.edu/resources/business-of-practice-blog/addressing-substance-abuse-behind-bars
- First Step Act Overview — Federal Bureau of Prisons. 2019-01-15. https://www.bop.gov/inmates/fsa/overview.jsp
Similar Articles
Read full bio of Sneha Tete
